State Street Corp Aligos Therapeutics, Inc. Transaction History
State Street Corp
- $2.21 Trillion
- Q1 2024
A detailed history of State Street Corp transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 97,423 shares of ALGS stock, worth $38,969. This represents 0.0% of its overall portfolio holdings.
Number of Shares
97,423
Previous 97,423
-0.0%
Holding current value
$38,969
Previous $64,000
48.44%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ALGS
# of Institutions
53Shares Held
46.2MCall Options Held
6.11MPut Options Held
200-
Armistice Capital, LLC New York, NY6.89MShares$2.76 Million0.09% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.39MShares$2.56 Million0.18% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$2.44 Million0.2% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$1.42 Million0.46% of portfolio
-
Altitude Crest Partners Inc. Stamford, CT2.84MShares$1.14 Million1.19% of portfolio
About Aligos Therapeutics, Inc.
- Ticker ALGS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,717,000
- Market Cap $15.9M
- Description
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...